

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Juha-Matti SAVOLA et al.

Serial Number: 10/534,091

Group Art Unit: 1618

Filing Date: May 6, 2005

Examiner: Gembah, Shirley V.

For: OROMUCOSAL FORMULATION AND PROCESS FOR PREPARING THE SAME

REQUEST FOR RECONSIDERATION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

June 23, 2010

Sir:

In response to the Official Action mailed February 25, 2010, a Petition for a one month Extension of Time submitted herewith, please reconsider this application in view of the following remarks. Claims 23 and 25-33 are pending.

The 35 U.S.C. § 103(a) rejection of claims 23, 25-29 and 31-33 over Huupponen et al., Clin.Pharmacol.Ther., 58, 506-11 (1995) in view of U.S. Patent No. 5,498,623 to Karjalainen et al. is traversed. The claimed method requires a specific administration route (absorption via oral mucosa) of fipamezole to a patient. The applicants have discovered a dangerous side effect (QTc prolongation) is avoided when fipamezole is oromucosally administered.